Robust dry eye assessment tool is found in compact survey

Article

A one-page, five-question questionnaire, called the DEQ-5, accurately identifies patients with Sjögren's syndrome and other patient populations with dry eye.

Key Points

Bloomington, IN-The differential diagnosis between dry eye related to Sjögren's syndrome and other classes of dry eye is a continuing challenge for the practitioner.

"Effective treatment requires an understanding of the etiology of dry eye," said Robin L. Chalmers, OD, FAAO, clinical trials consultant and adjunct professor at the Indiana University School of Optometry, Bloomington. "One important factor that can indicate etiology is the progression of ocular surface symptoms over the course of the day.

For most eye-care practitioners (ECPs), the patient case history is the starting point for diagnosis and treatment. Therefore, Dr. Chalmers said, "the more accurately this interview can distinguish Sjögren's syndrome patients from others with dry eye, the more effective and appropriate treatment can be. Use of a short questionnaire can standardize the information captured in the case history."

An underlying cause

Approximately 15% of people aged more than 40 years experience dry eye, and Sjögren's syndrome is a frequent, serious underlying cause of the problem. Chronic inflammation of the lacrimal and salivary glands, a distinguishing clinical sign of Sjögren's syndrome, leads to dry eye and dry mouth. Patients with Sjögren's syndrome experience aqueous tear deficiency caused by reduced aqueous tear volume, flow, and turnover resulting from impaired lacrimal gland function.

"With the DEQ-5, we have streamlined a validated dry eye assessment tool, the [Indiana] Dry Eye Questionnaire, to make it easier to administer. We have selected the questions that best correlated with patient self-assessment of the severity of dry eye," Dr. Chalmers explained. "The next step was to determine whether the five questions would provide a quantitative tool for the assessment of ocular surface symptoms in dry eye according to groups with distinct clinical diagnoses. The right scoring tool will help determine who may require further biopsy testing due to a suspicion of Sjögren syndrome, for example."

The study population comprised 260 subjects from dry eye studies conducted in 2002 and 2005, including 48 asymptomatic controls and 212 subjects with clinically diagnosed dry eye. Among the dry eye subjects, 57 had Sjögren's syndrome by the American-European 2002 criteria, and 155 had dry eye of other etiology as diagnosed by their ECP. All subjects completed the full DEQ.

Daypart reporting

By asking patients to rate their symptom frequency and intensity at different times of day (scale of 1 to 4 for frequency and 1 to 5 for severity), the researchers designed the DEQ-5 with the flexibility to avoid some of the problems associated with other dry eye questionnaires. Many such surveys require only yes or no answers regarding symptom frequency, a strategy that can differentiate patients with dry eye from those who do not have dry eye, but "does not capture the intensity of symptoms," Dr. Chalmers explained.

The DEQ-5 also addresses the patient's experience of late-day ocular surface dryness and discomfort, the most distinguishing symptoms of dry eye related to Sjögren's syndrome and other types of dry eye. Other such surveys do not query changes that occur over the course of the day, she said.

Average DEQ-5 scores were 2.7, 10.5 and 14.0 for controls, non-Sjögren's syndrome dry eye patients and Sjögren's syndrome patients, respectively, on a scale of 1 to 24. Differences between groups was significant (p = 0.000).

"It was apparent that these five questions can discriminate not only between normal and dry eye subjects but also between Sjögren's syndrome dry eye and those with dry eye of other etiologies," Dr. Chalmers said.

Based on the results, the researchers propose criteria for the DEQ-5 of >6 for suspicion of non-Sjögren's syndrome dry eye and >12 for Sjögren's syndrome dry eye.

For clinicians, the results underscore the need to ask the right questions in making diagnosis and treatment decisions in dry eye patients, Dr. Chalmers said. "I feel confident recommending the use of the DEQ-5 in practice," she said. "A high score on the DEQ-5 may indicate the need to do specific clinical tests for dry eye."

Further research will determine the DEQ-5's validity in measuring response to treatment in prospective clinical trials.

Recent Videos
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
Clark Chang, OD, MSA, MSc, FAAO, discussed the complexities of diagnosing keratoconus in his Rapid Fire presentation given at the American Academy of Optometry 2024 meeting.
Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, details the ease of genetic testing when diagnosing patients or reassessing a patient's diagnosis.
Gromacki, OD, FAAO, FSLS, emphasizes that corneal GP lenses remain an important part of a contact lens specialist's armamentarium
© 2024 MJH Life Sciences

All rights reserved.